ESMO Breast 2021 | Real-world use of bevacizumab in patients with breast cancer
Volkar Mueller, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the findings of a non-interventional trial evaluating the efficacy and toxicity of the use of bevacizumab in German routine clinical practice. In this analysis, progression-free survival and overall survival reflected known clinical trial data. In addition, patient satisfaction and physician’s assessment of patient satisfaction were found to be concordant. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.
Transcript (edited for clarity)
We actually also had a presentation on a non-interventional trial assessing the frequency and also the side effects, and some other aspects of the use of bevacizumab in German routine. And actually this was a large cohort with more than 2000 patients from more than 300 centers that were treated in the clinical routine setting within the approved setting of bevacizumab in combination with taxanes or with capecitabine...
We actually also had a presentation on a non-interventional trial assessing the frequency and also the side effects, and some other aspects of the use of bevacizumab in German routine. And actually this was a large cohort with more than 2000 patients from more than 300 centers that were treated in the clinical routine setting within the approved setting of bevacizumab in combination with taxanes or with capecitabine. And it confirmed many of the known data about PFS and overall survival, with a PFS of approximately 24 months and an overall survival approximately 13 months.
But also, we had some data on patients satisfactory with the treatment and compared this to the physicians’ assessment of patient satisfactory. That was interesting because it was quite concordant. And from the side effect we had no new [inaudible] with a lot of patients being over 65. I think it was really reassuring that the side effects were not higher as reported in the clinical trials.
Read more...
Disclosures
Volkar Mueller, MD, has received speaker honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva and Seattle Genetics; has received consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro and Nektar; has received institutional research support from Novartis, Roche, Seattle Genetics and Genentech; and has received travel grants from Roche, Pfizer and Daiichi Sankyo.
